| Předmět: |
|
| Zdroj: |
Hematology Week; 2024, p448-448, 1p |
| Abstrakt: |
A new report presents fresh data on pulmonary embolism, specifically focusing on the therapeutic management of intermediate-risk patients. The study was conducted in Moldova and included 18 patients with acute submassive pulmonary embolism. The researchers compared the use of thrombolysis (TT) with tissue-plasminogen activator (t-PA) to standard anticoagulation therapy. The study found that half-dose thrombolytic therapy significantly reduced death and hemodynamic decompensation in the first 7 days compared to anticoagulant therapy alone. The researchers concluded that patients with high-intermediate risk pulmonary embolism could benefit from reduced-dose thrombolytic therapy. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
